Patenting Biotechnology Inventions

Biotechnology patents cover some of the most valuable and most contested IP in the world — from gene therapies and monoclonal antibodies to CRISPR-based gene editing and diagnostic biomarkers. The legal frameworks governing biotech patentability vary more across jurisdictions than any other technology area, driven by fundamental policy differences about whether life forms, genes, and biological processes should be patentable.

What Is Patentable

Clearly Patentable (Most Jurisdictions)

Engineered proteins and antibodies (monoclonal antibodies, fusion proteins, antibody-drug conjugates), novel microorganisms created through genetic engineering, recombinant DNA constructs and vectors, methods of producing biological products (fermentation, cell culture, purification), diagnostic kits and reagents (as products, not as diagnostic methods), and novel drug delivery systems using biological materials.

Jurisdiction-Dependent

Isolated genes: Patentable in Europe (EU Biotech Directive 98/44/EC), Japan, China, and South Korea. Not patentable in the US since Myriad (2013) — isolated but unmodified naturally occurring DNA sequences are not eligible. Engineered sequences (cDNA, modified genes, synthetic constructs) remain patentable in the US.

CRISPR and gene editing tools: The methods are patentable in all major jurisdictions. The foundational CRISPR-Cas9 patents are held by the Broad Institute (US) and UC Berkeley/University of Vienna (EU), creating a licensing landscape that most gene editing inventors must navigate.

Diagnostic methods: Method claims for diagnosing disease face restrictions in Europe (Art. 53(c) — in vivo diagnostics excluded), India (Sec. 3(i)), and Australia (manner of manufacture challenge). In vitro diagnostic methods and diagnostic product claims are generally patentable.

Plants and animals: Excluded in India (Sec. 3(j)), limited in Europe (Art. 53(b) — essentially biological processes excluded, but products of technical processes may be patentable). Plant varieties are protected through PVP/PBR under the UPOV Convention.

Jurisdiction Comparison

The Budapest Treaty and Biological Deposits

When a biological material cannot be adequately described in writing — a specific microbial strain, a cell line, a hybridoma — it can be deposited at an International Depositary Authority (IDA) under the Budapest Treaty. The deposit satisfies enablement requirements: anyone can request a sample from the IDA after the patent publishes. Key IDAs include ATCC (US), DSMZ (Germany), CCTCC (China), NITE-IPOD (Japan), and KCCM (South Korea).

The Nagoya Protocol

The Nagoya Protocol on access to genetic resources requires that inventors who use genetic material sourced from another country obtain Prior Informed Consent and negotiate benefit-sharing agreements with the source country. EU Regulation 511/2014 implements compliance measures. Failure to demonstrate lawful access can complicate prosecution and enforcement. If your biotech invention uses genetic resources from a Nagoya Protocol member state, document the source, consent, and benefit-sharing terms before filing.

Sources

1. USPTO — MPEP § 2105-2107, Patentable Subject Matter — US guidance on patent eligibility for biotechnology and living subject matter
2. EPO Guidelines for Examination — Biotechnological Inventions — EPO rules on patenting genes, proteins, organisms, and biological processes
3. WIPO — Life Sciences and Intellectual Property — Global overview of biotech patent frameworks and policy
4. 35 U.S.C. § 101 — US statutory basis for patent eligibility, including Supreme Court limitations on natural phenomena